These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 10845828

  • 1. Long-term results with cyclosporine monotherapy in renal transplant patients: a multivariate analysis of risk factors.
    Montagnino G, Tarantino A, Maccario M, Elli A, Cesana B, Ponticelli C.
    Am J Kidney Dis; 2000 Jun; 35(6):1135-43. PubMed ID: 10845828
    [Abstract] [Full Text] [Related]

  • 2. A randomized study comparing three cyclosporine-based regimens in cadaveric renal transplantation. Italian Multicentre Study Group for Renal Transplantation (SIMTRe).
    Ponticelli C, Tarantino A, Segoloni GP, Cambi V, Rizzo G, Altieri P, Mastrangelo F, Castagneto M, Salvadori M, Valente U, Cossu M, Federico S, Pisani F, Montagnino G, Messina M, Arisi L, Carmellini M, Piredda G, Corbetta G.
    J Am Soc Nephrol; 1997 Apr; 8(4):638-46. PubMed ID: 10495794
    [Abstract] [Full Text] [Related]

  • 3. Long-term results of a randomized study comparing three immunosuppressive schedules with cyclosporine in cadaveric kidney transplantation.
    Montagnino G, Tarantino A, Segoloni GP, Cambi V, Rizzo G, Altieri P, Castagneto M, Salvadori M, Cossu M, Pisani F, Carmellini M, Mastrangelo F, Ferrara R, Ponticelli C.
    J Am Soc Nephrol; 2001 Oct; 12(10):2163-2169. PubMed ID: 11562416
    [Abstract] [Full Text] [Related]

  • 4. Prospective randomized study of azathioprine vs cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience.
    Gheith OA, Bakr MA, Fouda MA, Shokeir AA, Sobh M, Ghoneim M.
    Clin Exp Nephrol; 2007 Jun; 11(2):151-155. PubMed ID: 17593515
    [Abstract] [Full Text] [Related]

  • 5. Risk Factors Affecting Graft and Patient Survivals After Transplantation From Deceased Donors in a Developing Country: A Single-Center Experience.
    Ayar Y, Ersoy A, Ocakoglu G, Yildiz A, Oruc A, Soyak H, Calapkulu M, Sahin AB, Topal NB, Okeer E, Coskun B, Kaygisiz O, Kordan Y, Vuruskan H.
    Transplant Proc; 2017 Mar; 49(2):270-277. PubMed ID: 28219583
    [Abstract] [Full Text] [Related]

  • 6. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 7. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients.
    Grimbert P, Baron C, Fruchaud G, Hemery F, Desvaux D, Buisson C, Chopin D, Dahmane D, Remy P, Pastural M, Abbou C, Weil B, Lang P.
    Transpl Int; 2002 Nov; 15(11):550-5. PubMed ID: 12461659
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Krüger B, Ortuño J, Köhler H, Kunzendorf U, Stummvoll HK, Tabernero JM, Mühlbacher F, Rivero M, Arias M, European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group.
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [Abstract] [Full Text] [Related]

  • 9. Annual trends and triple therapy--1991-2000.
    Nishikawa K, Terasaki PI.
    Clin Transpl; 2001 May; ():247-69. PubMed ID: 12211788
    [Abstract] [Full Text] [Related]

  • 10. Steroid withdrawal in kidney transplant recipients: is it a safe option?
    Sanfey H, Haussman G, Isaacs I, Ishitani M, Lobo P, McCullough C, Pruett T.
    Clin Transplant; 1997 Oct; 11(5 Pt 2):500-4. PubMed ID: 9361950
    [Abstract] [Full Text] [Related]

  • 11. Maintenance cyclosporin monotherapy after renal transplantation--clinical predictors of long-term outcome.
    Touchard G, Hauet T, Cogny Van Weydevelt F, Hurault de Ligny B, Peyronnet P, Lebranchu Y, Toupance O, N'Doye P, Busson M.
    Nephrol Dial Transplant; 1997 Sep; 12(9):1956-60. PubMed ID: 9306349
    [Abstract] [Full Text] [Related]

  • 12. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
    Shabtai M, Ben-Haim M, Zemer D, Malinger-Saavedra P, Rosin D, Kuriansky J, Lustig S, Shabtai EL, Shapira Z, Ayalon A.
    Isr Med Assoc J; 2002 Nov; 4(11 Suppl):935-9. PubMed ID: 12455184
    [Abstract] [Full Text] [Related]

  • 13. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data.
    Joss N, Rodger RS, McMillan MA, Junor BJ.
    Transplantation; 2007 Mar 15; 83(5):582-7. PubMed ID: 17353778
    [Abstract] [Full Text] [Related]

  • 14. Long-term graft survival with or without donor-specific transfusion in cyclosporine era in one haplo-identical living-related renal transplant recipients beyond the first year: a 19-year experience.
    Satoh S, Sugimura J, Omori S, Seino K, Fujizuka I.
    Tohoku J Exp Med; 2002 Aug 15; 197(4):201-7. PubMed ID: 12434995
    [Abstract] [Full Text] [Related]

  • 15. Comparative analysis of azathioprine versus cyclosporine-based therapy in primary haplo-identical live-donor kidney transplantation: a 20-year experience.
    Gheith OA, Bakr MA, Fouda MA, Shokeir AA, Sobh M, Ghoneim M.
    Saudi J Kidney Dis Transpl; 2008 Jul 15; 19(4):564-70. PubMed ID: 18580014
    [Abstract] [Full Text] [Related]

  • 16. Outcome of cadaveric renal transplant patients treated for 10 years with cyclosporine: is chronic allograft nephropathy the major cause of late graft loss?
    Marcén R, Pascual J, Teruel JL, Villafruela JJ, Rivera ME, Mampaso F, Burgos FJ, Ortuño J.
    Transplantation; 2001 Jul 15; 72(1):57-62. PubMed ID: 11468535
    [Abstract] [Full Text] [Related]

  • 17. Effect of early cyclosporine levels on kidney allograft rejection.
    Johnson EM, Canafax DM, Gillingham KJ, Humar A, Pandian K, Kerr SR, Najarian JS, Matas AJ.
    Clin Transplant; 1997 Dec 15; 11(6):552-7. PubMed ID: 9408683
    [Abstract] [Full Text] [Related]

  • 18. Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study.
    Thierry A, Le Meur Y, Ecotière L, Abou-Ayache R, Etienne I, Laurent C, Vuiblet V, Colosio C, Bouvier N, Aldigier JC, Rerolle JP, Javaugue V, Gand E, Bridoux F, Essig M, Hurault de Ligny B, Touchard G.
    Transpl Int; 2016 Jan 15; 29(1):23-33. PubMed ID: 26729582
    [Abstract] [Full Text] [Related]

  • 19. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J, Kahan BD.
    Transplant Proc; 2011 Dec 15; 43(10):3657-68. PubMed ID: 22172822
    [Abstract] [Full Text] [Related]

  • 20. A randomized trial comparing triple-drug and double-drug therapy in renal transplantation. Analysis at 7 years.
    Montagnino G, Tarantino A, Banfi G, Aroldi A, Cesana B, Ponticelli C.
    Transplantation; 1994 Jul 27; 58(2):149-54. PubMed ID: 8042234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.